Deadline
Passed
Lead Plaintiff Deadline: August 17, 2020
According to the filed complaint, Co-Diagnostics and its directors and officers (including PhD-level scientists who should know better) made continual, knowing, and willful misstatements about the Company’s main product, a Covid-19 diagnostic test. These misstatements had the effect of pumping up the price of Co-Diagnostics’ stock while Company officers and directors exercised low-priced options and dumped their stock into the market. Co-Diagnostics’ fraudulent misstatements displayed a disregard for the basic scientific principles and cost investors to lose millions of dollars.